#1 Clinical Trials Search in Europe

[Al[18F]F]Fapi-74

[Al[18F]F]Fapi-74 is an innovative radioactive tracer being studied in various clinical trials for its potential to improve medical imaging. This article explores how this compound is being used to detect and diagnose different types of cancers and other conditions, offering new hope for more accurate and earlier detection of diseases.

Table of Contents

What is [AL[18F]F]FAPI-74?

[AL[18F]F]FAPI-74 is an innovative diagnostic tool being studied for its potential in detecting various types of cancers[1]. It is a radioactive tracer used in a special type of imaging called PET/CT (Positron Emission Tomography/Computed Tomography). This substance is also known by other names such as [18F]-AlF-FAPI-74 or simply 18F-FAPI-74[2].

How does [AL[18F]F]FAPI-74 work?

[AL[18F]F]FAPI-74 works by targeting a specific protein called Fibroblast Activation Protein (FAP). This protein is often found in high amounts in the tissue surrounding various types of tumors. When [AL[18F]F]FAPI-74 is injected into the body, it attaches to these FAP proteins, allowing doctors to see where cancer might be present using a PET/CT scanner[3].

What conditions is [AL[18F]F]FAPI-74 being studied for?

Research is ongoing to evaluate the effectiveness of [AL[18F]F]FAPI-74 in diagnosing and monitoring several types of cancers, including:

  • Progressive Pulmonary Fibrosis (PPF): A condition where the lungs become scarred over time[1].
  • Carcinoma of Unknown Primary (CUP): A type of cancer where doctors can’t determine where the cancer originally started[2].
  • Pancreatic cancer: Cancer that starts in the pancreas[4].
  • Colon cancer: Cancer that begins in the large intestine (colon)[5].
  • Prostate cancer: Cancer that occurs in the prostate gland[6].
  • Biliary tract cancers: Cancers that occur in the bile ducts[3].

How is [AL[18F]F]FAPI-74 administered?

[AL[18F]F]FAPI-74 is given as a solution for injection. It is typically administered through an intravenous (IV) injection, which means it’s injected directly into a vein[1][2]. The dose can vary, but studies have used amounts ranging from 250 to 400 MBq (megabecquerels, a unit of radioactivity)[4][6].

Potential benefits of [AL[18F]F]FAPI-74

The potential benefits of [AL[18F]F]FAPI-74 include:

  • Improved detection of cancer spread: It may help doctors identify if cancer has spread to lymph nodes or other parts of the body more accurately than current methods[4][5].
  • Identifying unknown primary tumors: In cases where the origin of cancer is unknown, [AL[18F]F]FAPI-74 might help locate the primary tumor[2].
  • Distinguishing between inflammation and active fibrosis: This could be particularly useful in conditions like pulmonary fibrosis[1].
  • Guiding treatment decisions: By providing more accurate information about a patient’s cancer, it could help doctors make better decisions about treatment[3].

Ongoing research and clinical trials

Several clinical trials are currently underway to evaluate the effectiveness of [AL[18F]F]FAPI-74 in various cancers. These studies aim to determine:

  • The accuracy of [AL[18F]F]FAPI-74 in detecting cancer spread[4][5].
  • How well it performs compared to other imaging techniques[6].
  • Its ability to guide treatment decisions and improve patient outcomes[3].
  • The optimal dose and timing for [AL[18F]F]FAPI-74 PET/CT scans[1][2].

Safety considerations

While [AL[18F]F]FAPI-74 appears promising, it’s important to note that it’s still being studied and is not yet approved for widespread clinical use. As with any medical procedure involving radiation, there are some safety considerations:

  • The procedure exposes patients to a small amount of radiation[1].
  • It’s not recommended for pregnant or breastfeeding women[3].
  • Patients with severely impaired kidney function may need special consideration[3].
  • As with any injection, there’s a small risk of allergic reaction[3].

Always consult with your healthcare provider to understand the potential risks and benefits of participating in a clinical trial or undergoing any new diagnostic procedure.

Aspect Details
Drug Name [Al[18F]F]Fapi-74
Administration Intravenous injection
Imaging Technique PET/CT scan
Conditions Studied Various cancers (lung, biliary tract, pancreatic, colon, prostate), unknown primary cancers
Potential Benefits Improved detection of metastases, identification of unknown primary cancers, differentiation between fibrosis and inflammation
Clinical Trial Phases Mostly diagnostic studies, some considered phase II/III
Key Endpoints Diagnostic accuracy, sensitivity, specificity, impact on patient management

FAQ

  • What is [Al[18F]F]Fapi-74? [Al[18F]F]Fapi-74 is a radioactive tracer used in PET/CT imaging. It's designed to bind to specific proteins in the body, helping doctors see certain types of cells or tissues more clearly in scans.
  • What types of conditions are being studied with [Al[18F]F]Fapi-74? Clinical trials are exploring its use in various cancers, including lung cancer, biliary tract cancer, pancreatic cancer, colon cancer, and prostate cancer. It's also being studied for its potential in identifying unknown primary cancers.
  • How is [Al[18F]F]Fapi-74 administered? It is typically given as an intravenous injection before a PET/CT scan. The amount used is measured in MBq (megabecquerels), which is a unit of radioactivity.
  • Are there any side effects of [Al[18F]F]Fapi-74? While specific side effects are still being studied in clinical trials, the safety and tolerability of [Al[18F]F]Fapi-74 PET/CT is one of the aspects being evaluated. As with any medical procedure involving radiation, there may be some risks, which should be discussed with a healthcare provider.
  • How might [Al[18F]F]Fapi-74 improve cancer diagnosis? [Al[18F]F]Fapi-74 may help in detecting cancer spread to lymph nodes or distant parts of the body more accurately than current methods. It could also potentially help in identifying the primary site of cancer in cases where it's unknown, which could lead to more targeted and effective treatments.

Ongoing Clinical Trials on [Al[18F]F]Fapi-74

  • A Study Using [AL[18F]F]FAPI-74 PET Scan to Improve Diagnosis and Monitoring of Giant Cell Arteritis in Patients with This Blood Vessel Disease

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of 18F-AlF-FAPI-74 PET/CT imaging compared to standard 18F-FDG PET/CT in patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on [18F]-AlF-FAPI-74 for Staging Advanced Stomach Cancer in Patients Using PET/CT and Laparoscopy

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on [18F]FAPI-74 for Better Cancer Imaging in Patients with Esophagogastric and Pancreatic Cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of 18F-FAPI-74 PET/CT Imaging for Detection of Lymph Node Metastases in Patients with Colon Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Effectiveness of [18F]FAPI-74 PET/CT for Detecting Lymph Node Spread in Patients with Pancreatic Cancer

    Recruiting

    2 1 1
    Investigated drugs:
    Finland

  • Study on PET/CT Imaging with [18F]-AlF-FAPI-74 for Identifying Fibrosis and Inflammation in Patients with Progressive Pulmonary Fibrosis

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Impact of [18F]-AlF-FAPI-74, Glucagon, and Hyoscine Butylbromide in Patients with Resectable Biliary Tract Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Diagnostic Accuracy of [18F]FAPI-74 PET/CT for Detecting Metastasis and Assessing Treatment Response in Gastric Cancer Patients

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Finland

  • Study on PET/CT Imaging with [18F]-AlF-FAPI-74 for Identifying Fibrosis and Inflammation in Patients with Progressive Pulmonary Fibrosis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • PET/CT: Positron Emission Tomography/Computed Tomography, a combined imaging technique that provides detailed pictures of areas inside the body
  • Radiotracer: A substance containing a radioactive atom that can be used to show how and where it is distributed in the body during imaging tests
  • Metastasis: The spread of cancer cells from the place where they first formed to another part of the body
  • Fibrosis: The formation of excess fibrous connective tissue in an organ or tissue, which can be a sign of disease or damage
  • Cholangiocarcinoma: A type of cancer that forms in the bile ducts
  • Carcinoma of Unknown Primary (CUP): A condition where cancer cells have spread in the body but the type of cancer is not known
  • Megabecquerel (MBq): A unit of measurement for radioactivity, often used to describe the amount of radiotracer used in medical imaging
  • FAPI: Fibroblast Activation Protein Inhibitor, a type of molecule that binds to certain proteins associated with cancer and other diseases
  • PSMA: Prostate-Specific Membrane Antigen, a protein found on the surface of prostate cancer cells

References

  1. http://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-18f-alf-fapi-74-for-identifying-fibrosis-and-inflammation-in-patients-with-progressive-pulmonary-fibrosis-2/
  2. http://clinicaltrials.eu/trial/study-to-identify-unknown-primary-cancer-using-18f-alf-fapi-74-pet-ct-for-patients-with-carcinoma-of-unknown-primary/
  3. http://clinicaltrials.eu/trial/study-on-the-impact-of-18f-alf-fapi-74-glucagon-and-hyoscine-butylbromide-in-patients-with-resectable-biliary-tract-cancer/
  4. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-18ffapi-74-pet-ct-for-detecting-lymph-node-spread-in-patients-with-pancreatic-cancer/
  5. http://clinicaltrials.eu/trial/study-on-the-accuracy-of-18ffapi-74-pet-ct-for-detecting-lymph-node-spread-in-patients-with-colon-cancer/
  6. http://clinicaltrials.eu/trial/study-on-metastatic-prostate-cancer-evaluating-18ffapi-74-and-piflufolastat-18f-for-patients-with-advanced-disease/